Skip to main content
TiumBio Co., Ltd. logo

TiumBio Co., Ltd. — Investor Relations & Filings

Ticker · 321550 ISIN · KR7321550006 KO Professional, scientific and technical activities
Open in API
Filings indexed 296 across all filing types
Latest filing 2023-01-06 Major Shareholding Noti…
Country KR South Korea
Listing KO 321550

About TiumBio Co., Ltd.

http://www.tiumbio.com/en/

TiumBio is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for rare and incurable diseases. The company's pipeline targets conditions with high unmet medical needs, including fibrotic diseases, cancer, and rare hematological disorders. Its lead assets include Merigolix (TU2670), an oral GnRH antagonist in clinical development for endometriosis and uterine fibroids, and TU7710, a long-acting recombinant activated factor VII for hemophilia. TiumBio also develops small molecule antagonists targeting the TGF-β signaling pathway for applications in oncology and fibrosis. The company advances its programs through clinical development and strategic global partnerships.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and special relationships of major shareholders (specifically Kim Hun-taek and related parties of TiumBio). This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2023-01-06 Korean
투자판단관련주요경영사항('TU2670 기술이전 및 공동개발 계약' 관련 마일스톤 기술료 수령)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details the receipt of a milestone payment related to a technology transfer agreement (TU2670). Since this is a specific regulatory disclosure of a material event that does not fit into categories like M&A, dividends, or share issues, it falls under the general regulatory filing category.
2023-01-02 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date and shareholder register closure for an upcoming Annual General Meeting (AGM). It does not contain the full meeting materials or proxy statements, but rather serves as a formal notice of the procedural steps for the meeting. Given the nature of the announcement regarding meeting preparation and the lack of a specific category for 'Record Date Notice', it falls under the general regulatory filing category.
2022-12-15 Korean
분기보고서 (2022.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for TiumBio, covering the period from January 1, 2022, to September 30, 2022. It contains detailed financial information, business descriptions, and management disclosures required for a quarterly filing. According to the provided definitions, a comprehensive financial report for a period shorter than a full fiscal year is classified as an Interim / Quarterly Report (IR). 9M 2022
2022-11-14 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides details such as the date, location, purpose, and where the IR materials will be posted. Since it is an announcement of an event and the availability of materials rather than the presentation itself, and it is under 5,000 characters, it fits the criteria for a Report Publication Announcement (RPA) or a general regulatory filing. Given the specific nature of announcing an IR event, RPA is the most accurate classification.
2022-10-27 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees and executives, including the number of shares, exercise price, and vesting conditions. This type of disclosure regarding capital structure changes and equity-based compensation falls under the category of 'Share Issue/Capital Change' (SHA) within the provided classification schema.
2022-09-29 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.